Month: June 2026

Introduction and Objective: The accumulation of adipose tissue occurs through adipocyte hypertrophy or adipogenesis, the latter refers to the proliferation and differentiation of adipose progenitor cells (APCs). Starting from middle age, adults often experience a notable increase in visceral adipose tissue mass, known as visceral adiposity, which is closely linked to a series of metabolic […]

Introduction and Objective: The Inflation Reduction Act capped out-of-pocket costs for insulin at $35 per 30-day supply for Medicare Part D beneficiaries in 2023 in a landmark policy change. This project measures the out-of-cap policy’s association with changes in out-of-pocket costs and insulin use for Part D beneficiaries. We also test whether the policy was […]

Introduction and Objective: People with T2D are at high risk for cardiovascular disease (CVD) and risk increases with poor glycemic control. This study evaluated the association between CGM use and the risk of major adverse cardiovascular events (MACE) among adults with T2D using real-world evidence.Methods: This retrospective study analyzed Truveta EHR data for people with […]

Introduction and Objective: We investigated the prevalence of organ impairment in people with T2D in primary care.Methods: People living with T2D and no prior heart disease were recruited from 5 sites and underwent standardised MRI (CoverScan) to measure fat (visceral, subcutaneous, epicardial, pericardial, hepatic, pancreatic), inflammation (hepatic, pancreatic, renal), muscle volume (myocardial, skeletal) and cardiac […]

Introduction and Objective: HDM1002 is an oral small molecule GLP-1RA under development for the treatment of T2DM and obesity. This study evaluated the efficacy and safety of HDM1002 in Chinese adult with T2DM inadequately controlled on diet and exercise(D&E) or metformin(Met).Methods: In this randomized, double-blind phase 2 study, patients were randomized in a 1:1:1:1:1 ratio […]

Introduction and Objective: Humans with obesity-related insulin resistance (IR) and metabolic dysfunction-associated steatotic liver disease (MASLD) show different mitochondrial alterations. While oxidative phosphorylation (OXPHOS) can be increased in liver, it may be decreased in visceral (VAT), but neither in subcutaneous adipose tissue (SAT) nor skeletal muscle (SM). However, it remains unclear how weight loss affects […]

Introduction and Objective: Instant blood-mediated inflammatory reaction (IBMIR) causes rapid loss of up to 50% of transplanted islet mass, primarily through inflammatory and coagulation pathways. Blocking these mediators is critical for improving graft survival. We hypothesized that aptamers targeting interleukin 1 beta (IL-1β), tumor necrosis factor-alpha (TNFα), and factor VIIa (FVIIa) could attenuate IBMIR and […]

Introduction and Objective: The optimal dietary carbohydrate intake for pregnant women is disputed internationally. Some authorities recommend consuming >175g/d of carbohydrate aiming to support safe placental function; others use carbohydrate restriction to ≤120g/d to reduce hyperglycemia in gestational diabetes. We assessed if consumption of a low (<175g/d) or very low (<120g/d) habitual carbohydrate intake was […]

Introduction and Objective: Activating and expanding brown adipose tissue (BAT) offer promising strategies to counteract obesity and cardiometabolic diseases. Due to their high metabolic activity, brown adipocytes act as a metabolic sink and improves glucose and lipid metabolism. Adipose depots are highly vascularized and innervated, containing an extensive network of capillaries and sympathetic nerves that […]

Introduction and Objective: Little is known about how diet quality is related to gestational glycemia and neonatal birthweight.Methods: From 2/2023 to 2/2024, singleton gravidas without preexisting diabetes and enrolled in GO MOMs, a multicenter study of glycemia across pregnancy, completed Automated Self-Administered 24-Hour Dietary Assessment recalls: up to 3 at 10-20 wks’ gestation, and up […]